Which tumor markers are recommended for the evaluation and monitoring of ovarian and other female gynecologic malignancies?

Recommended Tumor Markers for Ovarian and Female Gynecologic Malignancies

CA-125 is the primary tumor marker for epithelial ovarian cancer, elevated in approximately 80% of patients with stage II or higher disease, and should be measured in conjunction with HE4 to improve diagnostic accuracy. 1

Epithelial Ovarian Cancer

Primary Markers

• CA-125 remains the cornerstone marker, elevated in ~80% of epithelial tumors at diagnosis and correlating with disease status in most cases, often rising 2-5 months before clinical detection of relapse 2
• HE4 (Human Epididymis Protein 4) combined with CA-125 significantly improves both sensitivity and specificity for early-stage detection, particularly for serous and endometrioid subtypes 1, 3
• The NCCN does not currently recommend using HE4 and CA-125 algorithms (such as ROMA) for determining malignancy status of undiagnosed pelvic masses, despite FDA approval 2

Supplementary Markers

• CA 19-9 should be measured for mucinous histology, as these tumors often fail to express CA-125; it also helps distinguish ovarian from gastrointestinal primaries when combined with CEA 1, 4
• CEA is most commonly associated with mucinous ovarian cancers and aids in differential diagnosis 3, 4
• A high CA-125/CEA ratio enhances specificity for distinguishing ovarian from gastrointestinal primary tumors 1

Critical Limitations

• CA-125 lacks specificity and can be falsely elevated in endometriosis, benign ovarian cysts, pregnancy, pelvic inflammatory disease, pancreatic cancer, and liver cirrhosis 1
• Only ~50% of stage I cases demonstrate elevated CA-125, limiting its utility for early detection 1

Germ Cell Tumors

For germ cell tumors, measure AFP, beta-hCG, and LDH at diagnosis and use for post-treatment surveillance when elevated at baseline. 1

• Alpha-fetoprotein (AFP) is produced by yolk sac tumors, embryonal carcinomas, polyembryomas, and immature teratomas 2, 1
• Beta-hCG is produced by choriocarcinomas, embryonal carcinomas, polyembryomas, and at low levels by some dysgerminomas 1, 5
• Lactate dehydrogenase (LDH) serves as the primary marker for dysgerminoma 1, 5
• AFP levels should be specifically considered in women younger than 35 years presenting with a pelvic mass 2

Sex-Cord Stromal Tumors

Inhibin is the primary serum marker for granulosa-cell tumors and other sex-cord stromal tumors. 1

• Measure inhibin every 2-4 months during the first 2 years after treatment, then every 6 months thereafter for surveillance 1
• Inhibin is essential for both initial diagnosis and long-term monitoring of these tumor types 1, 5

Endometrial Cancer

• CA-125 contributes to approximately 15% of recurrence detection in asymptomatic patients and is elevated in more than half of patients with advanced stage or high-grade histology 1
• Routine CA-125 testing is not advised for all endometrial cancer patients; reserve it for selected cases with advanced disease, serous histology, or elevated pretreatment levels 1, 4

Initial Workup for Undiagnosed Pelvic Mass

When evaluating a suspicious pelvic mass, measure the following tumor markers if clinically indicated 2:

• CA-125 (primary marker)
• Inhibin (if sex-cord stromal tumor suspected)
• AFP (especially in women <35 years)
• Beta-hCG (to assess for germ cell tumors and exclude pregnancy)

Molecular Testing Requirements

For all patients with high-grade non-mucinous tubo-ovarian carcinoma, perform BRCA1/2 mutation testing (germline and/or somatic) at diagnosis, regardless of stage. 1

• Genomic instability assays are recommended for BRCA-wild-type, high-grade, FIGO stage III-IV disease to guide first-line maintenance therapy decisions 1

Surveillance Recommendations

Ovarian Cancer Follow-Up

• Physical examination and symptom review: every 3 months for years 0-2, every 4-6 months for years 2-3, every 6 months for years 3-5, then yearly 2
• CA-125 monitoring is optional at all time points; discuss pros and cons with patients, as routine monitoring does not improve survival 2
• Routine imaging (chest x-ray, CT, MRI, PET-CT) has insufficient data to support routine use in asymptomatic patients 2
• When recurrence is suspected based on symptoms, examination, or CA-125 elevation, obtain CT chest/abdomen/pelvis; use PET-CT as adjunct when CT is indeterminate 2

Common Pitfalls

• Do not use tumor markers for population screening—elevation does not equate to early-stage disease detection, and most markers lack sufficient sensitivity for this purpose 1
• Avoid fine-needle aspiration for diagnosing ovarian cancer in presumed early-stage disease to prevent cyst rupture and peritoneal spillage 2
• Interpret CA-125 carefully considering age, menopausal status, and comorbidities that may cause false elevation 1, 6
• In patients with negative CA-125 at diagnosis, serial measurements of CA 19-9, CA 72-4, or CA 15-3 may provide useful monitoring alternatives 4